The TIC industry (also written TICC when compliance services are included) sits at the intersection of trade, safety and trust. Much of it isn’t optional: every smartphone, barrel of crude, or batch of cancer drugs is tested, inspected or certified by a third party because law, regulation, or insurance demands it. That mandated, recurring demand compounds alongside GDP and global trade. The top 10 players generated US$44 billion in 2025, yet the industry remains highly fragmented, ranging from single-lab specialists to global names with billions in revenue, a structure that makes it fertile ground for consolidation.
Two structural forces explain the resilience. First, regulation only goes one way: each new framework creates demand for an outside party with a stamp. Second, complexity is compounding. Multi-jurisdiction supply chains, recycled-content claims, novel modalities in pharma, AI-enabled embedded software, all force buyers and sellers to import trust from a credentialed third party. TIC provides exactly that service.
This article reviews seven years of audited financial disclosures from the global Top 10 players. The dataset is hand-extracted from 67 annual reports, 10-Ks and S-1s spanning fiscal years 2019 through 2025, converted to USD at constant 2024 average exchange rates and normalised to a common six-vertical taxonomy. It is intended to be a baseline that an investor or strategist can run their own questions against.
Industry scale and trajectory
Estimates of the market’s size vary with definition. Bureau Veritas puts the total TIC market at more than €200 billion (roughly US$230 billion), but reckons only about half is outsourced to third parties, the rest stays inside company and government labs. SGS sizes that addressable, outsourced slice at US$160 billion in 2023, growing to US$190 billion by 2027, or +4% to +5% a year. Against either figure, the Top 10’s US$44 billion of revenue shows how fragmented the industry remains.
The Top 10 collectively grew from approximately US$32 billion of revenue in 2019 to US$44 billion in 2025, a 5.6% CAGR at constant FX. That figure includes two important compositional changes:
- Applus+ was a public-market constituent of the peer set until October 2024, when it was taken private by TDR Capital and I Squared Capital;
- UL Solutions arrived on the public stage in April 2024 via its NYSE listing.
On a like-for-like basis covering the eight names with continuous disclosure, the CAGR is closer to 4.5%, comfortably above global nominal GDP growth over the period but materially below management aspirations communicated to investors at the start of the decade.
The aggregate disguises a meaningful spread inside the peer set. ALS Limited grew at a 10.3% CAGR, the strongest in the cohort, driven by aggressive M&A in life sciences (Wessling Germany, York Analytical) layered on top of a robust commodities cycle. Eurofins posted 8.1%, a number that flatters the underlying trajectory because the 2020-22 window was distorted by COVID-19 testing revenue worth approximately €2.8 billion cumulatively. Stripping that out, organic Eurofins growth has been mid-single-digits, ahead of peers but not transformational.
At the other end of the table, SGS posted just 0.9% CAGR over the period. The Swiss leader has run into a series of cyclical and structural headwinds: currency translation (the franc strengthened 17-19% against the euro between 2019 and 2025), the divestment of a low-margin US oil & gas business, and a multi-year programme of portfolio pruning under former CEO Frankie Ng. New CEO Géraldine Picaud, appointed in March 2024, has reset the strategy with a ‘Strategy 27’ plan and a renewed M&A engine: the 19 deals completed in 2025.
Bureau Veritas, by contrast, has run a more measured 4.0% CAGR with a more consistent organic engine, and its ‘LEAP|28’ strategy launched in 2024 is essentially a doubling-down on the existing model rather than a reset.
The German private trio, DEKRA, TÜV SÜD, TÜV Rheinland, sit in a tight band of 4.5%-6.1% CAGR. Their growth is, by the standards of the listed peer group, surprisingly comparable. The German non-profit and mutual-association structures, often dismissed by capital-markets investors as governance-constrained, have not obviously been a brake on top-line expansion.
The consolidation wave
TIC is in the middle of its loudest decade of M&A.
First, there were a number of megadeals in the industry:
- In January 2025, SGS and Bureau Veritas publicly confirmed talks toward a merger of equals, a combination that would have created an entity with revenues approaching US$15 billion and left several verticals with only two credible global providers. The talks were terminated within weeks.
- In April 2024, UL Solutions, the 130-year-old US safety certification body, completed its NYSE IPO, with its parent UL Standards & Engagement selling approximately US$946 million of shares in an all-secondary offering, the first US TIC listing at multi-billion-dollar scale.
- In October 2024, TDR Capital together with I Squared Capital completed a take-private of Applus+ at €12.78 per share, implying an equity value of roughly €1.6 billion.
Below those headlines, the bolt-on acquisition machinery has accelerated. Eurofins is the cohort’s structural acquirer, completing between 26 and 59 deals per year throughout the period, with cumulative transactions exceeding 260 since 2019. The company’s model is to industrialise the integration: decentralised P&L ownership, proprietary laboratory IT, hub-and-spoke laboratory networks, fast multiple arbitrage.
Bureau Veritas has historically run a more curated programme of two to five mid-sized deals per year, but stepped up sharply in 2024 (10 deals) and 2025 (9 deals) under the LEAP|28 strategy.
SGS’s M&A reset is one of the more interesting subplots. Through 2019-2023 the group completed an average of three deals per year and explicitly signalled capital discipline. From 2024 onwards, that has reversed: 11 deals in 2024, 19 deals in 2025, and the largest acquisition in SGS’s history, ATS Inc., signed in July 2025 at an enterprise value of approximately US$1.3 billion and closed in January 2026.
The consolidation logic is straightforward. TIC is a fragmented business, Top 10 account for an estimated 25% of the outsourced TIC market, or roughly a fifth of the total market once in-house work is included, with the long tail comprising hundreds of national laboratories, family-owned inspection bureaus, and specialist certifiers.
Profitability
The TIC industry’s profitability and valuation profile ranges from mid-single-digit margins at the association- and foundation-owned German groups to the mid-twenties, and the spread is structural rather than cyclical.
Three major clusters are visible. The high-margin cluster, UL Solutions (25.9% margin), Eurofins (22.5%), Intertek (18.1%) and ALS (17.2%), has a common feature: pricing power. The margin bases differ by company, adjusted EBITDA for UL Solutions and Eurofins and adjusted operating margin for the rest, so read the clusters as directional rather than a like-for-like table. UL’s mark is the de facto entry ticket to the US market for consumer electronics and industrial products, demanded by retailers, insurers and code authorities; Eurofins is the global default for pharmaceutical contract testing; Intertek’s Corporate Assurance and Health & Safety divisions are professional-services-like rather than commodity-testing. Pricing is set by the value of the credential, not by lab labour cost. ALS is the partial exception: its margin comes from hub-lab scale in cyclical assay volumes rather than credential value.
The middle cluster, SGS (16.0%) and Bureau Veritas (16.3%), is what most investors think of as the ‘TIC margin profile’. The two share a similar mix of high-margin certification with lower-margin lab inspection and industry services, and both have been remarkably stable: SGS oscillated between 14.7% and 16.5% across the period; BV ranged 13.4% to 16.3%.
The low cluster is occupied by the German private peers: DEKRA at 5.5% adjusted EBIT margin (reported 2.4% in 2025 distorted by goodwill impairments), TÜV SÜD at 5.9%, TÜV Rheinland at 8.1%. Three factors compress profitability here. First, the Mobility/Vehicle-Inspection franchise that drives a large part of DEKRA and TÜV SÜD revenue is a regulated-tariff business: the price per test is effectively set by the state, leaving the operator with operational leverage but not pricing power. Second, the German cost base is high: expensive labour, mandatory works-council co-determination, high social charges. Third, the not-for-profit governance structure removes the capital-discipline pressure that listed peers face.
Vertical exposure and growth pockets
Where the industry’s revenue actually comes from matters as much as how fast it grows.
Mapping each company’s reported segments to a normalised six-vertical taxonomy: Mobility & Transport / Consumer Products / Industrial & Infrastructure / Life Sciences & Healthcare / Natural Resources & Environment / Certification & Business Assurance, reveals an industry of specialists, not generalists.
Three patterns stand out. First, the ‘pure play’ anchors. Eurofins is, by some distance, the most concentrated Life Sciences business in the cohort: pharmaceutical, food, clinical diagnostics and environmental testing together account for the overwhelming majority of revenue. ALS sits at the opposite end of a comparable spectrum: 42% of revenue is from commodities-related geochemistry, metallurgy and coal/iron-ore inspection. Both companies are deliberate specialists; both have outperformed the cohort on growth (Eurofins 8.1% CAGR, ALS 10.3%) over 2019-2025.
Second, the diversified players. SGS, Bureau Veritas and Intertek each operate across all six verticals with no single segment exceeding 50% of revenue. The diversification has historically been viewed as defensive, but it also makes capital allocation harder. None of the three has a ‘winning’ vertical to which they can decisively re-route capital; instead, each must defend share across multiple battlegrounds where they face the specialists. Bureau Veritas’s LEAP|28 plan explicitly addresses this tension by selecting six ‘must-win’ sub-verticals to over-invest in (renewable energy, cybersecurity, sustainability assurance and so on).
Third, the Mobility-anchored Germans. DEKRA, TÜV SÜD and TÜV Rheinland derive a disproportionate share of revenue from automotive testing, services such as periodic technical inspection, homologation, EV battery and charging certification. DEKRA’s estimated 55% Mobility exposure is the highest in the cohort. This concentration creates two issues: a regulated-tariff drag on margins, and a more existential question about the long-run inspection volume of an EV-only, lower-failure-mode car parc. Both DEKRA and TÜV SÜD are actively diversifying: TÜV SÜD’s 2024 acquisition of Carspect Group (vehicle inspection in Sweden and the Baltics) and the new ranges of EV battery and AI-system certification services are direct responses.
Of the six verticals, Life Sciences & Healthcare grew fastest over 2019-2025 (driven by pharma, food safety, ESG). Certification & Business Assurance, including ISO certifications, ESG audit and cyber assessments, grew second-fastest, and is the segment with the highest forward growth expectations across the peer group, supported by the EU Cyber Resilience Act and by CSRD assurance demand from the largest EU reporters (the 2026 Omnibus reform narrowed CSRD to companies with 1,000+ employees and EUR 450m+ turnover). Consumer Products has been more sluggish post-2022 as the China-to-West retail testing volumes have softened with consumer demand.
Geographic concentration
Eight of the global Top 10 TIC companies are headquartered in Europe; only UL Solutions is US-based and ALS is from Australia. That headquarter geography overstates the European tilt of revenue: the listed peers run truly global operations, but it does shape where decision-making, capital allocation and talent acquisition take place.
The revenue map separates the cohort into three clusters. The ‘global’ cluster: SGS (33% Europe, 21% Americas, 34% APAC) and Bureau Veritas (35/27/28/10) is the most balanced. Both have spent two decades building APAC capability, and SGS’s 34% Asia-Pacific share is the highest in the peer set. The ‘European-anchored’ cluster: DEKRA (90%), TÜV SÜD (76%), TÜV Rheinland (61%), Applus+ (53% prior to delisting), Eurofins (51%) collects majority of the revenue in Europe. The ‘Americas-tilted’ cluster, UL Solutions (45% Americas), ALS (42%) and Intertek (38%, as disclosed by major-country reporting), has a different exposure profile.
The implication for growth is uncomfortable for the European-anchored names. Europe is forecast to grow nominal GDP at sub-3% over the medium term; Asia-Pacific at high-single-digits. For DEKRA, TÜV SÜD and TÜV Rheinland, organic outperformance will require a multi-year programme of APAC investment that none of them has historically excelled at. Eurofins is interesting, already 51% Europe, but in the middle of an explicit pivot toward North America, partly because its largest pharma customers are in Boston, Cambridge and the Bay Area.
UL Solutions, despite its IPO and ~$3 billion of revenue, is the only US-listed TIC company of meaningful scale. Several explanations have been advanced: the lack of an obvious roll-up acquirer in private equity until recently (now changed by the Applus deal); the historical strength of European testing standards and certifications that built early-mover advantage in global trade; the fragmentation of US state-level regulatory regimes. A US-led consolidator entering the European market, or a stronger UL Solutions extending its industrial-certification franchise outside North America, could be a possible development over the future years.
People and productivity
TIC is a people business: about 430,000 people are employed across the Top 10 cohort at end-2025 (excluding Applus+, post-delisting). The headcount grew from approximately 397,000 at the start of 2019.
Productivity, measured as revenue per employee, spans a wide range: from US$77,000 at SGS to US$209,000 at UL Solutions. The cause is mix. UL has the highest share of certification and software-and-advisory revenue in the cohort; certification is a high-value-add, light-headcount business. SGS, conversely, employs large numbers of inspectors and technicians in emerging markets where revenue per FTE is structurally lower. Bureau Veritas (US$85k/FTE), with its large field-services Industry and Buildings & Infrastructure divisions, sits in the same productivity band as SGS. Eurofins (US$120k/FTE) and Intertek (US$97k/FTE) sit between the two.
Outlook
Three themes will shape the next five years. First, consolidation continues. The SGS-Bureau Veritas talks were the highest-profile evidence of a strategic conviction that scale matters; below the radar the consolidation continues for the smaller TIC players. We expect continued interest in M&A from the top of the league table, and a continued bolt-on pace from Eurofins, BV, and SGS. Private equity, which is backing a wide range of TIC players outside of the Top 10 (e.g. Trescal, Normec), has now entered one of the largest companies in the space.
Second, the regulatory tailwind is real and is asymmetric to the cohort. Multiple new regulations generate net-new TIC demand. The certifiers with strong existing ESG and cyber franchises: DNV (not in this cohort, but adjacent), BV’s Certification division, SGS’s Business Assurance, Intertek’s Corporate Assurance could be the beneficiaries.
Third, the mobility transition is a double-edged sword. EV adoption removes some classical inspection volume (no oil changes, fewer mechanical wear items) but adds high-value certifications (battery state-of-health, charging infrastructure compliance, software-over-the-air audits). The German vehicle-inspection champions face the most strategic risk and the most upside, depending on whether they can transition from a tariff-regulated, volume-driven model to a higher-margin, certification-led one.
On a five-year view, the cohort’s aggregate revenue is plausibly heading toward US$60 billion at constant FX, implying a cohort CAGR of 6-7%, modestly above the 5.6% delivered in 2019-2025. Margin expansion is achievable but harder; the German private peers face the most pressure, but also have the most room to improve. The biggest swing factor remains M&A: a successful SGS-BV merger, in any form, would re-set the competitive map.
About Aventis Advisors
At Aventis Advisors, we specialize in providing top-tier M&A advisory services across business services and TIC sector. We are experienced in TIC M&A advisory for international clients.
We believe the world would be better off with fewer (but better quality) M&A deals done at the right moment for the company and its owners. Our goal is to provide honest, insight-driven advice, clearly laying out all the options for our clients – including the one to keep the status quo.
Get in touch with us to discuss your M&A needs in the TIC industry.
